Please provide your email address to receive an email when new articles are posted on . The FDA approved updated labeling to remove aspirin as part of routine care after implant of Abbott’s fully ...

PHILADELPHIA -- Dropping aspirin from the antithrombotic regimen after HeartMate 3 left ventricular assist device (LVAD) implantation appeared safer than the usual combination approach in the ...

The ARIES-HM3 Randomized Clinical Trial assessed the safety and efficacy of excluding aspirin from the antithrombotic regimen in patients with advanced heart failure who have undergone implantation of ...

Patients with preexisting indications for aspirin therapy—including those with a history of revascularization, stroke, or peripheral vascular disease—may not need the drug after receiving the ...

PHILADELPHIA, PA—Adding to a growing list of medical situations in which aspirin appears to do more harm than good, the ARIES HM3 trial has shown that it can safely be dropped from the antithrombotic ...

New research highlighted how aspirin is unnecessary in antithrombotic regimens for patients with advanced heart failure and fully magnetically levitated left ventricular assist devices (LVADs). Among ...

Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has ...

Please provide your email address to receive an email when new articles are posted on . In patients with advanced HF on a LVAD, removing aspirin from the antithrombotic regimen was safe. Avoiding ...

A groundbreaking study recently published in JAMA indicates that aspirin may not be necessary as part of an antithrombotic regimen for patients with a fully magnetically levitated left ventricular ...